{"id":25895,"date":"2026-01-27T17:02:15","date_gmt":"2026-01-27T15:02:15","guid":{"rendered":"https:\/\/makingpharmaindustry.it\/?p=25895"},"modified":"2026-01-27T17:02:15","modified_gmt":"2026-01-27T15:02:15","slug":"genenta-becomes-a-strategic-industrial-platform","status":"publish","type":"post","link":"https:\/\/makingpharmaindustry.it\/en\/business-en-2\/genenta-becomes-a-strategic-industrial-platform\/","title":{"rendered":"Genenta becomes a Strategic Industrial Platform"},"content":{"rendered":"

In response to evolving market dynamics and strategic opportunities, Genenta Science S.p.A (Nasdaq: GNTA) is embarking on a strategic transformation to evolve into a next-generation strategic industrial consolidator<\/strong>\u00a0focused on acquiring privately held<\/strong>\u00a0businesses <\/strong>operating in national-security regulated sectors<\/strong>\u00a0contemplated by the Italian Golden Power<\/a>[1]<\/a>\u00a0legislation. The Company intends to target majority ownership in companies with established operating profitability<\/strong>, typically generating up to approximately \u20ac5 million in EBITDA<\/a>[2]<\/a>. In this context, Genenta plans to adopt the new corporate name of Saentra Forge S.p.A.<\/strong>\u00a0with a new Nasdaq ticker symbol of SAEN<\/a>[3]<\/a><\/strong>.<\/p>\n

Saentra Forge intends to pursue a value-creation strategy by acquiring targets at private-market valuations<\/strong>and integrating these companies under Saentra Forge. Through this integration, the Company will seek to enhance these businesses through operational upgrades, institutional-grade governance, and improved financial visibility. Execution<\/strong>\u00a0has commenced with ATC, a defense-sector company.<\/p>\n

Genenta Science (Nasdaq: GNTA)<\/strong>, which will be renamed as Saentra Forge (Nasdaq: SAEN, pending effectiveness), will
\nbe a next-generation strategic consolidator focused on privately held specialized companies operating in Italian national
\nsecurity regulated sectors, with activities spanning cybersecurity, defense, aerospace, and biotechnology\/biosecurity.<\/p><\/blockquote>\n

First Industrial Integration<\/h2>\n

ATC<\/strong>\u00a0is a private company operating as a high-precision manufacturer of tactical rifles and special-forces weapon systems, and competition-grade sporting firearms<\/strong>.\u00a0Genenta has entered into a binding agreement according to which it will provide funding for ATC through a series of reserved capital increases, via a performance-based and staged acquisition to support operations with the ultimate goal of owning a controlling position in ATC upon the achievement of defined performance milestones. The transaction has received<\/strong>\u00a0the required clearance<\/strong>\u00a0under the Golden Power<\/strong>\u00a0regulatory framework. ATC holds\u00a0UAMA<\/a>[4]<\/a>\u00a0and SeRNI<\/a>[5]<\/a>\u00a0export-control licenses<\/strong>, NATO<\/a>[6]<\/a>\u00a0qualifications,<\/strong>\u00a0and authorization from the Italian Ministry of Defense<\/strong>, and its platforms are used by special-forces units and include combat-proven systems<\/strong>. Genenta expects to fund a total of EUR 5.1 million <\/strong>in several performance-driven tranches. ATC is projecting revenues<\/strong>\u00a0of approximately \u20ac4.0 million<\/strong>\u00a0in 2026<\/strong>, increasing to around \u20ac9.0 million by 2027<\/strong>. The company operates with a solid net cash position<\/strong>\u00a0and no outstanding bank debt<\/strong>, reflecting a disciplined management structure. On the profitability side, ATC forecasts EBITDA<\/strong>\u00a0of more than \u20ac2.0 million in 2026<\/strong>, with management expecting EBITDA to approximately double in 2027<\/strong>. See “Non-GAAP Information” below for a discussion of the measure EBITDA. In addition, ATC anticipates closing 2026 with a positive cash balance exceeding \u20ac2.0 million, and expects to further strengthen its liquidity position by ending 2027 with cash exceeding \u20ac5.0 million.<\/p>\n

Praexidia Foundation<\/a>[7]<\/a>\u00a0Joins as Strategic Long-Term Shareholder of the Company<\/h2>\n

At the core of the Company\u2019s strategic configuration is the Praexidia Foundation, which has become a shareholder<\/a>[8]<\/a>. The Praexidia Foundation is a private law foundation bringing together senior figures from Italian government institutions, the defense industry, and the armed forces,<\/strong>\u00a0supporting long-term strategic alignment and stability.<\/p>\n

The Company, the Foundation, and Pierluigi Paracchi, Founder and CEO, have entered into a\u00a0shareholders\u2019 agreement<\/strong>\u00a0that provides for consultation rights on significant corporate transactions and a renewable\u00a0five-year lock-up<\/strong>, thereby reinforcing long-term alignment, continuity, and effective control. The sovereign-aligned nature of the Praexidia Foundation further strengthens the Company\u2019s governance framework, supporting regulatory coherence, strategic continuity, and\u00a0efficient execution of acquisitions<\/strong>\u00a0in sectors subject to the Golden Power regulations.<\/p>\n

Biotech Clinical Updates\u00a0and Partnering Strategy<\/h2>\n

The Company has reached key clinical milestones that it believes will now enable the advancement of its cell therapy platform through partnerships with leading pharmaceutical and biotech companies, with the potential to accelerate development, market access, and strategic value.\u00a0\u00a0DC Advisory<\/strong>\u00a0has been engaged to serve as the Company’s exclusive financial advisor for partnership initiatives<\/strong>.\u00a0Such initiatives are envisaged to prioritize leveraging the technology platform for broader applications and indications,\u00a0particularly in solid tumors that are inherently difficult to target, while\u00a0pursuing\u00a0combination therapy approaches, or continuing\u00a0development of Temferon as a glioblastoma multiforme (GBM) monotherapy. During this process, the Company will continue to advance its trial in GBM, pursue\u00a0a\u00a0capital-efficient approach<\/strong>\u00a0to advancing additional opportunities through partnerships and does not plan to internally advance the GU study and other clinical trials at this time.<\/p>\n

The Company expects its cash, cash equivalents, and marketable securities<\/strong>\u00a0at December 31, 2025, to be approximately $33<\/strong>\u00a0<\/strong>million<\/strong>, compared to $17.7 million at June 30, 2025. The increase is primarily due to the Company\u2019s registered direct offering with certain institutional investors as indicated in the Company\u2019s Form 6-K filed with the Securities & Exchange Commission on October 28, 2025.<\/p>\n

For more information, please see the Company’s Form 6-K filed with the Securities and Exchange Commission today.<\/p>\n

Riferences<\/em><\/h3>\n

<\/a>[1]<\/a>\u00a0\u201cGolden Power\u201d is Italy\u2019s investment screening framework \u2014 broadly comparable to CFIUS in the United States, the IEF regime in France, and the United Kingdom\u2019s NSI Act \u2014 and covers strategic domains such as biotechnology, biosecurity, defense, cybersecurity, AI-driven intelligence, aerospace, quantum technologies, secure communications, and critical infrastructure.<\/p>\n

<\/a>[2]<\/a>\u00a0See “Non-GAAP Information” below for a discussion of the measure EBITDA.<\/p>\n

<\/a>[3]<\/a>\u00a0The new corporate name and the new Nasdaq ticker symbol will become effective upon approval by its shareholders at a Shareholders\u2019 Meeting scheduled for March 25-26, 2026.<\/p>\n

<\/a>[4]<\/a>\u00a0UAMA is the Italian government authority responsible for authorizing and overseeing the export and transfer of defense-related materials under applicable Italian and international regulations.<\/p>\n

<\/a>[5]<\/a>\u00a0SeRNI: SeRNI, the Italian National Register of Defense and National Security Companies, certifies authorized defense and national security operators.<\/p>\n

<\/a>[6]<\/a>\u00a0North Atlantic Treaty Organization<\/p>\n

<\/a>[7]<\/a>\u00a0www.fondazionepraexidia.org<\/a><\/u><\/p>\n

<\/a>[8]<\/a>\u00a0Praexidia Foundation has become a shareholder of the Company through a donation of shares by Pierluigi Paracchi.<\/p>\n","protected":false},"excerpt":{"rendered":"

Genenta Science S.p.A. is transforming into a strategic industrial consolidator targeting majority stakes in profitable Italian companies operating in national-security regulated sectors. The transformation includes the integration of ATC as the first industrial transaction, a corporate rebranding to Saentra Forge S.p.A., strengthened governance through the Praexidia Foundation, and continued advancement of the Company\u2019s biotech platform through partnerships, supported by a strong cash position.<\/p>\n","protected":false},"author":32,"featured_media":25897,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[1004],"tags":[],"class_list":{"0":"post-25895","1":"post","2":"type-post","3":"status-publish","4":"format-standard","5":"has-post-thumbnail","7":"category-business-en-2"},"yoast_head":"\nGenenta becomes a Strategic Industrial Platform - MakingPharmaIndustry<\/title>\n<meta name=\"description\" content=\"Genenta Science announces a strategic transformation into a biotech, defense, and national security industrial platform, including rebranding as Saentra Forge.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/makingpharmaindustry.it\/en\/business-en-2\/genenta-becomes-a-strategic-industrial-platform\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Genenta becomes a Strategic Industrial Platform - MakingPharmaIndustry\" \/>\n<meta property=\"og:description\" content=\"Genenta Science announces a strategic transformation into a biotech, defense, and national security industrial platform, including rebranding as Saentra Forge.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/makingpharmaindustry.it\/en\/business-en-2\/genenta-becomes-a-strategic-industrial-platform\/\" \/>\n<meta property=\"og:site_name\" content=\"MakingPharmaIndustry\" \/>\n<meta property=\"article:published_time\" content=\"2026-01-27T15:02:15+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/makingpharmaindustry.it\/wp-content\/uploads\/2026\/01\/ChatGPT-Image-27-gen-2026-16_01_06.png\" \/>\n\t<meta property=\"og:image:width\" content=\"1536\" \/>\n\t<meta property=\"og:image:height\" content=\"1024\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Valentina Parrella\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Valentina Parrella\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"5 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\/\/makingpharmaindustry.it\/en\/business-en-2\/genenta-becomes-a-strategic-industrial-platform\/#article\",\"isPartOf\":{\"@id\":\"https:\/\/makingpharmaindustry.it\/en\/business-en-2\/genenta-becomes-a-strategic-industrial-platform\/\"},\"author\":{\"name\":\"Valentina Parrella\",\"@id\":\"https:\/\/makingpharmaindustry.it\/en\/#\/schema\/person\/64f06c0b8ba01c2f0f5d68f582ad16f0\"},\"headline\":\"Genenta becomes a Strategic Industrial Platform\",\"datePublished\":\"2026-01-27T15:02:15+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/makingpharmaindustry.it\/en\/business-en-2\/genenta-becomes-a-strategic-industrial-platform\/\"},\"wordCount\":904,\"image\":{\"@id\":\"https:\/\/makingpharmaindustry.it\/en\/business-en-2\/genenta-becomes-a-strategic-industrial-platform\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/makingpharmaindustry.it\/wp-content\/uploads\/2026\/01\/ChatGPT-Image-27-gen-2026-16_01_06.png\",\"articleSection\":[\"Business\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/makingpharmaindustry.it\/en\/business-en-2\/genenta-becomes-a-strategic-industrial-platform\/\",\"url\":\"https:\/\/makingpharmaindustry.it\/en\/business-en-2\/genenta-becomes-a-strategic-industrial-platform\/\",\"name\":\"Genenta becomes a Strategic Industrial Platform - MakingPharmaIndustry\",\"isPartOf\":{\"@id\":\"https:\/\/makingpharmaindustry.it\/en\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\/\/makingpharmaindustry.it\/en\/business-en-2\/genenta-becomes-a-strategic-industrial-platform\/#primaryimage\"},\"image\":{\"@id\":\"https:\/\/makingpharmaindustry.it\/en\/business-en-2\/genenta-becomes-a-strategic-industrial-platform\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/makingpharmaindustry.it\/wp-content\/uploads\/2026\/01\/ChatGPT-Image-27-gen-2026-16_01_06.png\",\"datePublished\":\"2026-01-27T15:02:15+00:00\",\"author\":{\"@id\":\"https:\/\/makingpharmaindustry.it\/en\/#\/schema\/person\/64f06c0b8ba01c2f0f5d68f582ad16f0\"},\"description\":\"Genenta Science announces a strategic transformation into a biotech, defense, and national security industrial platform, including rebranding as Saentra Forge.\",\"breadcrumb\":{\"@id\":\"https:\/\/makingpharmaindustry.it\/en\/business-en-2\/genenta-becomes-a-strategic-industrial-platform\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/makingpharmaindustry.it\/en\/business-en-2\/genenta-becomes-a-strategic-industrial-platform\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/makingpharmaindustry.it\/en\/business-en-2\/genenta-becomes-a-strategic-industrial-platform\/#primaryimage\",\"url\":\"https:\/\/makingpharmaindustry.it\/wp-content\/uploads\/2026\/01\/ChatGPT-Image-27-gen-2026-16_01_06.png\",\"contentUrl\":\"https:\/\/makingpharmaindustry.it\/wp-content\/uploads\/2026\/01\/ChatGPT-Image-27-gen-2026-16_01_06.png\",\"width\":1536,\"height\":1024},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/makingpharmaindustry.it\/en\/business-en-2\/genenta-becomes-a-strategic-industrial-platform\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/makingpharmaindustry.it\/en\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Genenta becomes a Strategic Industrial Platform\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/makingpharmaindustry.it\/en\/#website\",\"url\":\"https:\/\/makingpharmaindustry.it\/en\/\",\"name\":\"MakingPharmaIndustry\",\"description\":\"Luogo di incontro\u00a0per approfondire e discutere le pi\u00f9 importanti tematiche del mondo Pharma, dalla ricerca e sviluppo al manufacturing, dal mercato al business\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/makingpharmaindustry.it\/en\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\/\/makingpharmaindustry.it\/en\/#\/schema\/person\/64f06c0b8ba01c2f0f5d68f582ad16f0\",\"name\":\"Valentina Parrella\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/secure.gravatar.com\/avatar\/9489e527cae2d980412b4296f66093487551a8e1010c544334080d6b66e72eeb?s=96&d=mm&r=g\",\"url\":\"https:\/\/secure.gravatar.com\/avatar\/9489e527cae2d980412b4296f66093487551a8e1010c544334080d6b66e72eeb?s=96&d=mm&r=g\",\"contentUrl\":\"https:\/\/secure.gravatar.com\/avatar\/9489e527cae2d980412b4296f66093487551a8e1010c544334080d6b66e72eeb?s=96&d=mm&r=g\",\"caption\":\"Valentina Parrella\"},\"url\":\"https:\/\/makingpharmaindustry.it\/en\/author\/valentina-parrella\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Genenta becomes a Strategic Industrial Platform - MakingPharmaIndustry","description":"Genenta Science announces a strategic transformation into a biotech, defense, and national security industrial platform, including rebranding as Saentra Forge.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/makingpharmaindustry.it\/en\/business-en-2\/genenta-becomes-a-strategic-industrial-platform\/","og_locale":"en_US","og_type":"article","og_title":"Genenta becomes a Strategic Industrial Platform - MakingPharmaIndustry","og_description":"Genenta Science announces a strategic transformation into a biotech, defense, and national security industrial platform, including rebranding as Saentra Forge.","og_url":"https:\/\/makingpharmaindustry.it\/en\/business-en-2\/genenta-becomes-a-strategic-industrial-platform\/","og_site_name":"MakingPharmaIndustry","article_published_time":"2026-01-27T15:02:15+00:00","og_image":[{"width":1536,"height":1024,"url":"https:\/\/makingpharmaindustry.it\/wp-content\/uploads\/2026\/01\/ChatGPT-Image-27-gen-2026-16_01_06.png","type":"image\/png"}],"author":"Valentina Parrella","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Valentina Parrella","Est. reading time":"5 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/makingpharmaindustry.it\/en\/business-en-2\/genenta-becomes-a-strategic-industrial-platform\/#article","isPartOf":{"@id":"https:\/\/makingpharmaindustry.it\/en\/business-en-2\/genenta-becomes-a-strategic-industrial-platform\/"},"author":{"name":"Valentina Parrella","@id":"https:\/\/makingpharmaindustry.it\/en\/#\/schema\/person\/64f06c0b8ba01c2f0f5d68f582ad16f0"},"headline":"Genenta becomes a Strategic Industrial Platform","datePublished":"2026-01-27T15:02:15+00:00","mainEntityOfPage":{"@id":"https:\/\/makingpharmaindustry.it\/en\/business-en-2\/genenta-becomes-a-strategic-industrial-platform\/"},"wordCount":904,"image":{"@id":"https:\/\/makingpharmaindustry.it\/en\/business-en-2\/genenta-becomes-a-strategic-industrial-platform\/#primaryimage"},"thumbnailUrl":"https:\/\/makingpharmaindustry.it\/wp-content\/uploads\/2026\/01\/ChatGPT-Image-27-gen-2026-16_01_06.png","articleSection":["Business"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/makingpharmaindustry.it\/en\/business-en-2\/genenta-becomes-a-strategic-industrial-platform\/","url":"https:\/\/makingpharmaindustry.it\/en\/business-en-2\/genenta-becomes-a-strategic-industrial-platform\/","name":"Genenta becomes a Strategic Industrial Platform - MakingPharmaIndustry","isPartOf":{"@id":"https:\/\/makingpharmaindustry.it\/en\/#website"},"primaryImageOfPage":{"@id":"https:\/\/makingpharmaindustry.it\/en\/business-en-2\/genenta-becomes-a-strategic-industrial-platform\/#primaryimage"},"image":{"@id":"https:\/\/makingpharmaindustry.it\/en\/business-en-2\/genenta-becomes-a-strategic-industrial-platform\/#primaryimage"},"thumbnailUrl":"https:\/\/makingpharmaindustry.it\/wp-content\/uploads\/2026\/01\/ChatGPT-Image-27-gen-2026-16_01_06.png","datePublished":"2026-01-27T15:02:15+00:00","author":{"@id":"https:\/\/makingpharmaindustry.it\/en\/#\/schema\/person\/64f06c0b8ba01c2f0f5d68f582ad16f0"},"description":"Genenta Science announces a strategic transformation into a biotech, defense, and national security industrial platform, including rebranding as Saentra Forge.","breadcrumb":{"@id":"https:\/\/makingpharmaindustry.it\/en\/business-en-2\/genenta-becomes-a-strategic-industrial-platform\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/makingpharmaindustry.it\/en\/business-en-2\/genenta-becomes-a-strategic-industrial-platform\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/makingpharmaindustry.it\/en\/business-en-2\/genenta-becomes-a-strategic-industrial-platform\/#primaryimage","url":"https:\/\/makingpharmaindustry.it\/wp-content\/uploads\/2026\/01\/ChatGPT-Image-27-gen-2026-16_01_06.png","contentUrl":"https:\/\/makingpharmaindustry.it\/wp-content\/uploads\/2026\/01\/ChatGPT-Image-27-gen-2026-16_01_06.png","width":1536,"height":1024},{"@type":"BreadcrumbList","@id":"https:\/\/makingpharmaindustry.it\/en\/business-en-2\/genenta-becomes-a-strategic-industrial-platform\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/makingpharmaindustry.it\/en\/"},{"@type":"ListItem","position":2,"name":"Genenta becomes a Strategic Industrial Platform"}]},{"@type":"WebSite","@id":"https:\/\/makingpharmaindustry.it\/en\/#website","url":"https:\/\/makingpharmaindustry.it\/en\/","name":"MakingPharmaIndustry","description":"Luogo di incontro\u00a0per approfondire e discutere le pi\u00f9 importanti tematiche del mondo Pharma, dalla ricerca e sviluppo al manufacturing, dal mercato al business","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/makingpharmaindustry.it\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/makingpharmaindustry.it\/en\/#\/schema\/person\/64f06c0b8ba01c2f0f5d68f582ad16f0","name":"Valentina Parrella","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/9489e527cae2d980412b4296f66093487551a8e1010c544334080d6b66e72eeb?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/9489e527cae2d980412b4296f66093487551a8e1010c544334080d6b66e72eeb?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/9489e527cae2d980412b4296f66093487551a8e1010c544334080d6b66e72eeb?s=96&d=mm&r=g","caption":"Valentina Parrella"},"url":"https:\/\/makingpharmaindustry.it\/en\/author\/valentina-parrella\/"}]}},"_links":{"self":[{"href":"https:\/\/makingpharmaindustry.it\/en\/wp-json\/wp\/v2\/posts\/25895","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/makingpharmaindustry.it\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/makingpharmaindustry.it\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/makingpharmaindustry.it\/en\/wp-json\/wp\/v2\/users\/32"}],"replies":[{"embeddable":true,"href":"https:\/\/makingpharmaindustry.it\/en\/wp-json\/wp\/v2\/comments?post=25895"}],"version-history":[{"count":2,"href":"https:\/\/makingpharmaindustry.it\/en\/wp-json\/wp\/v2\/posts\/25895\/revisions"}],"predecessor-version":[{"id":25899,"href":"https:\/\/makingpharmaindustry.it\/en\/wp-json\/wp\/v2\/posts\/25895\/revisions\/25899"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/makingpharmaindustry.it\/en\/wp-json\/wp\/v2\/media\/25897"}],"wp:attachment":[{"href":"https:\/\/makingpharmaindustry.it\/en\/wp-json\/wp\/v2\/media?parent=25895"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/makingpharmaindustry.it\/en\/wp-json\/wp\/v2\/categories?post=25895"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/makingpharmaindustry.it\/en\/wp-json\/wp\/v2\/tags?post=25895"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}